FGF Signalling in the Self-Renewal of Colon Cancer Organoids.
Aged
Aged, 80 and over
Cell Differentiation
/ drug effects
Cell Proliferation
/ drug effects
Cell Self Renewal
/ drug effects
Colonic Neoplasms
/ genetics
Female
Fibroblast Growth Factor 2
/ pharmacology
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Male
Middle Aged
Neoplasm Staging
Neoplastic Stem Cells
/ drug effects
Organoids
/ drug effects
Primary Cell Culture
Signal Transduction
/ drug effects
Spheroids, Cellular
/ drug effects
Tumor Cells, Cultured
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 11 2019
22 11 2019
Historique:
received:
23
07
2019
accepted:
04
11
2019
entrez:
24
11
2019
pubmed:
24
11
2019
medline:
25
11
2020
Statut:
epublish
Résumé
The progression of colorectal cancer (CRC) is supposedly driven by cancer stem cells (CSC) which are able to self-renew and simultaneously fuel bulk tumour mass with highly proliferative and differentiated tumour cells. However, the CSC-phenotype in CRC is unstable and dependent on environmental cues. Fibroblast growth factor 2 (FGF2) is essential and necessary for the maintenance of self-renewal in adult and embryonic stem cells. Investigating its role in self-renewal in advanced CRC patient-derived organoids, we unveiled that FGF-receptor (FGFR) inhibition prevents organoid formation in very early expanding cells but induces cyst formation when applied to pre-established organoids. Comprehensive transcriptome analyses revealed that the induction of the transcription factor activator-protein-1 (AP-1) together with MAPK activation was most prominent after FGFR-inhibition. These effects resemble mechanisms of an acquired resistance against other described tyrosine kinase inhibitors such as EGF-receptor targeted therapies. Furthermore, we detected elevated expression levels of several self-renewal and stemness-associated genes in organoid cultures with active FGF2 signalling. The combined data assume that CSCs are a heterogeneous population while self-renewal is a common feature regulated by distinct but converging pathways. Finally, we highlight FGF2 signalling as one of numerous components of the complex regulation of stemness in cancer.
Identifiants
pubmed: 31758153
doi: 10.1038/s41598-019-53907-7
pii: 10.1038/s41598-019-53907-7
pmc: PMC6874569
doi:
Substances chimiques
Fibroblast Growth Factor 2
103107-01-3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17365Références
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Mol Cancer Res. 2007 Dec;5(12):1263-75
pubmed: 18171984
Nat Genet. 2015 Apr;47(4):320-9
pubmed: 25706628
Int J Mol Med. 2017 Jan;39(1):9-20
pubmed: 27909729
Nat Med. 2019 Oct;25(10):1607-1614
pubmed: 31591597
Cell Stem Cell. 2016 Jun 2;18(6):827-838
pubmed: 27212702
Nat Med. 2011 Sep 04;17(10):1225-7
pubmed: 21892181
Nat Commun. 2019 Jul 2;10(1):2919
pubmed: 31266962
Science. 1997 May 9;276(5314):955-60
pubmed: 9139660
Philos Trans R Soc Lond B Biol Sci. 2013 Sep 23;368(1629):20130014
pubmed: 24062584
Stem Cell Res. 2015 May;14(3):270-82
pubmed: 25771201
Stem Cells. 2007 Feb;25(2):455-64
pubmed: 17038665
Adv Biol Regul. 2016 Sep;62:37-49
pubmed: 27220739
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Inflammopharmacology. 2005;13(1-3):113-25
pubmed: 16259733
Oncogene. 2003 Oct 16;22(46):7155-69
pubmed: 14562044
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Mol Biol Cell. 2005 Mar;16(3):1131-41
pubmed: 15635089
Cancer Discov. 2014 Nov;4(11):1269-80
pubmed: 25293556
Biochim Biophys Acta. 2012 Apr;1823(4):850-60
pubmed: 22273505
Sci Transl Med. 2019 Oct 9;11(513):
pubmed: 31597751
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
Cancer Res. 2017 Apr 1;77(7):1763-1774
pubmed: 28202525
Sci Signal. 2011 Jul 26;4(183):pe34
pubmed: 21791701
Cancer Cell. 2012 Jun 12;21(6):777-92
pubmed: 22698403
PLoS One. 2013 Jun 25;8(6):e67031
pubmed: 23825608
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Dev Dyn. 2017 Apr;246(4):344-352
pubmed: 28198118
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Eur J Med Chem. 2017 Jan 27;126:476-490
pubmed: 27914362
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Nat Rev Cancer. 2018 Jul;18(7):407-418
pubmed: 29692415
Cell Signal. 2014 Mar;26(3):570-9
pubmed: 24308963
Nat Genet. 2004 Oct;36(10):1117-21
pubmed: 15378062
Am J Cancer Res. 2014 Nov 19;4(6):608-28
pubmed: 25520855
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
J Biol Chem. 2007 Feb 9;282(6):4045-56
pubmed: 17142811
Methods Mol Biol. 2013;1035:247-59
pubmed: 23959997
Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10356-61
pubmed: 11526241
J Vis Exp. 2010 Dec 08;(46):
pubmed: 21178966
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13308-11
pubmed: 26460009
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
Stem Cells Dev. 2016 Aug 1;25(15):1119-33
pubmed: 27308945
Oncotarget. 2016 Nov 22;7(47):76684-76692
pubmed: 27713123
Science. 2018 Feb 23;359(6378):920-926
pubmed: 29472484
Semin Cell Dev Biol. 2014 Apr;28:49-56
pubmed: 24631357